Chidan Tuihuang granule modulates gut microbiota to influence NOD1/RIPK2 pathway in cholestatic liver injury recovery
Phytomedicine · 2024
DOI: 10.1016/j.phymed.2024.156164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2024. Verfasst von Yuan Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Chi…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Nod1 Signaling Adaptor Protein, Drugs, Chinese Herbal, Receptor-Interacting Protein Serine-Threonine Kinase 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Natural Science Foundation of Sichuan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Cholestatic liver injury (CLI), which occurs if bile acids are imbalanced and the liver becomes inflamed, is difficult to treat effectively OBJECTIVE: We investigated how the Chinese patent medicine Chidan Tuihuang granule (CDTH) ameliorates cholestatic liver injury with a focus on its effects on the NOD1/RIPK2 pathway and intestinal flora METHODS: We used an ANIT-induced SD rat model of CLI to evaluate the therapeutic effects of CDTH. The experimental design included control, model, UDCA (ursodeoxycholic acid) and CDTH treatment groups. UHPLC-Q-Orbitrap-HRMS was used to analyse the blood components of CDTH. The efficacy of CDTH was assessed by liver function tests, histopathological examination (HE and TUNEL staining), transmission electron microscopy, and ELISA to measure apoptosis and inflammatory markers. Mechanistic insights were obtained using transcriptomics and RT-qPCR, while alterations in the expression of key proteins were studied using western blotting, immunohistochemistry, and immunofluorescence. Furthermore, the impact of CDTH on the gut microbiota and its associated metabolite, meso-2,6-diaminopimelic acid (DAP), which is linked to NOD1 activation, was examined and confirmed through in vitro RESULTS: The experimental results demonstrated a notable elevation in serum levels of AST, ALT, ALP, TBA, TBIL, and DBIL in the rats belonging to the model group, accompanied by the infiltration of inflammatory cells, hepatocyte degeneration, and necrosis in the liver tissue. CDTH administration significantly improved liver function and cholestasis indicators. Transmission electron microscopy and TUNEL staining revealed a marked reduction in liver cell apoptosis with CDTH treatment. ELISA results showed that CDTH effectively reduced inflammatory markers. Transcriptomic analysis showed that CDTH inhibited the NOD1/RIPK2 pathway, resulting in a significant decrease in the expression of NOD1, RIPK2 and associated genes in liver tissue. Gut microbiota analysis demonstrated that CDTH regulated intestinal flora structure, reducing the abundance of DAP-producing Gram-negative bacteria such as lactobacilli. In vitro experiments confirmed that CDTH enhanced cell viability by downregulating the DAP-mediated NOD1/RIPK2 signaling pathway secreted by intestinal bacteria CONCLUSION: CDTH ameliorated liver damage in cholestatic rats by inhibiting the NOD1/RIPK2 signaling pathway through regulation of gut flora and downregulation of DAP metabolites.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- Sichuan Industrial Institute of Antibiotics, School of Pharmacy, Chengdu University.
- State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China. Electronic address: tobymaxiao@163.com.
- Hospital of Chengdu University of Traditional Chinese Medicine, School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China. Electronic address: Lyy520qiqi@163.com.
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany. Electronic address: xiaohulu@uni-mainz.de.
- Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Mainz, Germany. Electronic address: efferth@uni-mainz.de.
Förderung
- Natural Science Foundation of Sichuan Province
- National Natural Science Foundation of China
Zitieren
APA
Chen, Y., Hu, Q., Zhang, W., Gong, Q., Yan, J., Wang, Z., Zhou, Z., Ma, X., Li, Y., Lu, X., & Efferth, T. (2024). Chidan Tuihuang granule modulates gut microbiota to influence NOD1/RIPK2 pathway in cholestatic liver injury recovery. Phytomedicine. https://doi.org/10.1016/j.phymed.2024.156164
Vancouver
Chen Y, Hu Q, Zhang W, Gong Q, Yan J, Wang Z, et al. Chidan Tuihuang granule modulates gut microbiota to influence NOD1/RIPK2 pathway in cholestatic liver injury recovery. Phytomedicine. 2024. doi:10.1016/j.phymed.2024.156164
BibTeX
@article{Chen2024,
author = {Chen, Yuan and Hu, Qichao and Zhang, Wenwen and Gong, Qianqian and Yan, Jin and Wang, Zexin and Zhou, Zongyuan and Ma, Xiao and Li, Yeyu and Lu, Xiaohua and Efferth, Thomas},
title = {Chidan Tuihuang granule modulates gut microbiota to influence NOD1/RIPK2 pathway in cholestatic liver injury recovery},
journal = {Phytomedicine},
year = {2024},
doi = {10.1016/j.phymed.2024.156164}
}
EUVIMED